December 12, 2001Pfizer Has Recalled Rescriptor 200 mg tablets
New York, NY (SafetyAlerts)
- The Food and Drug Administration (FDA) said that Pfizer Inc.
Rescriptor 200 mg tablets (delavirdine mesylate tablets).
This is the first public notice of
recall issued by the FDA.
Rescriptor 200 mg tablets (delavirdine mesylate tablets), NDC 0009-7576-01,
Bottles of 180 tablets, Recall # D-041-2.
Lot no. 17DSJ Exp. date 11/01.
Pfizer Inc., New York, NY, by letter on 10/26/01.
Pharmacai & UpJohn Barceloneta, Puerto Rico. Firm initiated recall is
Lowered therapeutic effectiveness.
VOLUME OF PRODUCT IN COMMERCE